GC Biopharma Corp.
A Proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients with Fabry Disease
- Conditions
- Fabry Disesase
- Interventions
- Drug: HM15421/GC1134A
- First Posted Date
- 2025-03-05
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- GC Biopharma Corp
- Target Recruit Count
- 18
- Registration Number
- NCT06858397
- Locations
- πΊπΈ
David Geffen School of Medicine UCLA, UCLA Health, Los Angeles, California, United States
πΊπΈUniversity of Kansas School of Medicine, Kansas City, Kansas, United States
πΊπΈUniversity of Minnesota, Minneapolis, Minnesota, United States
Phase 1 Study of GC1130A in Pediatric Patients With Sanfilippo Syndrome Type A (MPS IIIA)
- First Posted Date
- 2024-08-23
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- GC Biopharma Corp
- Target Recruit Count
- 9
- Registration Number
- NCT06567769
- Locations
- π―π΅
National Center for Child Health and Development, Setagaya, Tokyo, Japan
πΊπΈUCSF Benioff Children's Hospital, Oakland, California, United States
πΊπΈUniversity of Minnesota, Minneapolis, Minnesota, United States
A Study to Evaluate the Safety, PK of GC2129A in Healthy Volunteers Under Fed Conditions
- Conditions
- Healthy Volunteers
- Interventions
- Drug: GC2129A(Period 1)Drug: Linaglptin 5mg and Metformin Hydrocholoride 1000mg(Period 1)Drug: Linaglptin 5mg and Metformin Hydrochloride 1000mg(Period 2)Drug: GC2129A(Period 2)
- First Posted Date
- 2023-02-15
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- GC Biopharma Corp
- Target Recruit Count
- 34
- Registration Number
- NCT05729386
- Locations
- π°π·
H Plus YangJi Hospital, Seoul, Korea, Republic of
A Study to Evaluate the Safety, PK of GC2129A in Healthy Volunteers Under Fasting Conditions
- Conditions
- Healthy Volunteers
- Interventions
- Drug: GC2129A(Period 1)Drug: Linaglptin 5mg and Metformin Hydrocholoride 1000mg(Period 1)Drug: Linaglptin 5mg and Metformin Hydrochloride 1000mg(Period 2)Drug: GC2129A(Period 2)
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2023-01-30
- Lead Sponsor
- GC Biopharma Corp
- Target Recruit Count
- 50
- Registration Number
- NCT05703984
- Locations
- π°π·
H Plus YangJi Hospital, Seoul, Korea, Republic of
A Study to Investigate the Safety and Efficacy of Undiluted Intravenous Infusion of I.V.-Hepabig Inj.
- Conditions
- Hepatitis B
- Interventions
- Biological: Undiluted I.V.-Hepabig inj(GC5103)Biological: Diluted I.V.-Hepabig inj(GC5103)
- First Posted Date
- 2023-01-17
- Last Posted Date
- 2023-02-14
- Lead Sponsor
- GC Biopharma Corp
- Target Recruit Count
- 200
- Registration Number
- NCT05686759
- Locations
- π°π·
Asan Medical Center, Seoul, Korea, Republic of
An Open-label, Bridging Study of BARYCELA Inj. in Healthy Vietnamese Children Aged Between 12 Months to 12 Years
- Conditions
- Varicella Zoster Virus Infection
- Interventions
- Biological: MG1111
- First Posted Date
- 2022-12-23
- Last Posted Date
- 2022-12-23
- Lead Sponsor
- GC Biopharma Corp
- Target Recruit Count
- 250
- Registration Number
- NCT05664152
A Phase 1b Study to Assess the Safety, Tolerability, PK and PD of MG1113 in Hemophilia Patient
- Conditions
- Hemophilia
- Interventions
- Biological: MG1113
- First Posted Date
- 2022-08-09
- Last Posted Date
- 2022-08-25
- Lead Sponsor
- GC Biopharma Corp
- Target Recruit Count
- 15
- Registration Number
- NCT05493631
- Locations
- π°π·
GC Biopharma Corp., Yongin-si, Gyeonggi-do, Korea, Republic of
A Study to Evaluate the Safety, Tolerability, PK and PD of Intracerebroventricular GC1123 in Patients with MPS β ‘
- Conditions
- Hunter SyndromeMucopolysaccharidosis II
- Interventions
- First Posted Date
- 2022-06-16
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- GC Biopharma Corp
- Target Recruit Count
- 12
- Registration Number
- NCT05422482
- Locations
- π°π·
Pusan National University Yangsan Hospital, Pusan, Korea, Republic of
π°π·Seoul National University, Seoul, Korea, Republic of
π°π·Samsung Medical Center, Seoul, Korea, Republic of